SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date and the companys amended application emphasizing upper-limb function data. Bullish traders interpret the longer-term data, rare-disease policy discussions and recent commercial hiring as encouraging signs, while skeptics cite prior FDA concerns and say approval remains uncertain.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention for its breakout ahead of the expected Q3 earnings report, with traders focused on BRIUMVIs growth and possible further upside. Buyout and short-squeeze chatter is prominent but speculative; some traders instead attribute the move to earnings expectations and the companys commercial momentum.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall after early 2027 has fueled a sharp selloff and concern about future pricing and revenue. Traders disagree over whether the warning signals sustained pressure or is only a preliminary estimate, pointing to CMSs more stable outlook while criticizing CorMedixs lack of clarification.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS REGAL Phase 3 leukemia trial reached its prespecified event threshold, triggering final analysis and putting the GPS survival readout in focus. Traders are sharply divided over whether GPS will show a benefit or whether control-arm outcomes and trial assumptions could undermine the bull case, amid volatile trading and speculation about short positioning.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens PAPZIMEOS commercial launch and stronger-than-expected quarterly results, including a move to profitability, are driving bullish discussion about its growth prospects. Traders also debate whether potential INO-3107 competition could challenge PAPZIMEOS and whether heavy short interest is amplifying the stocks moves.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its quarterly report is fueling concern about slowing ad growth, analyst target cuts, and weakness across advertising-related stocks. Traders debate whether the decline reflects deteriorating prospects or has overshot the companys growth and cash-generation fundamentals, with earnings seen as a key test.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp Nasdaq selloff tied to weakness in technology and semiconductor stocks, with traders debating whether concerns about AI spending and earnings justify more downside or whether the decline is an oversold dip to buy. The late-session rebound prompted some dip-buying optimism, but bearish traders continued to warn that the correction may not be over.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,396.41. The last known price of BNB is 698.79071116 USD and is down -6.08 over the last 24 hours. It is currently trading on 3523 active market(s) with $4,017,835,584.29 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

Binances reported large-scale security breach and temporary suspension of deposits and withdrawals dominate discussion, with traders worried about exchange security, customer withdrawals, and possible broader crypto-market fallout. Some expect deeper losses or an FTX-like crisis, while others argue Binance can cover customer losses and that the sell-off has been limited.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings, fueled by Eylea HD sales and higher Sanofi collaboration revenue from Dupixent, drove a sharp share-price jump and breakout discussion. Traders largely welcomed the results, while some debated whether newer drugs can sustain growth; the upcoming cemdisiran decision also drew attention.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Silvers sharp selloff, amid inflation concerns and expectations of higher interest rates, is driving attention to SLV. Traders are split between calling the decline an oversold buying opportunity and warning that selling may continue, with some blaming market manipulation without evidence.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Coty's Q1 Earnings on Deck: Key Factors You Should Understand

COTY's fiscal first-quarter results are likely to reflect softer sales and margin pressures, despite innovation, brand initiatives and cost-control efforts.

Coty Strengthens AI Search Strategy Through Brandlight Partnership

COTY partners with Brandlight to boost AI-driven beauty discovery, optimize digital marketing and strengthen brand visibility across generative search platforms.

Coty and Brandlight Unveil Strategic Partnership to Strengthen Brand Visibility Across AI-powered Search and Discovery

Coty Inc. (NYSE: COTY), one of the world's largest beauty companies, and Brandlight, the market leader in AI visibility, today announced a strategic partnership to unleash the potential of brand discovery and visibility across AI assistants and generative AI search platforms. As consumer discovery...

Coty Sharpens Climate Goals, Cuts Water and Packaging Use in FY26 Sustainability Report

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020096366/en/ Today, Coty Inc. (NYSE: COTY) (Paris: COTY) (Coty or the Company) released its Fiscal Year 2026 (FY26) Sustainability Report under its Beauty That Lasts...

Coty Launches Global Fragrance Club, a New Community for the Voices Shaping the Future of Fragrance

Coty (NYSE:COTY) today announced the launch of the Coty Fragrance Club, a global community that brings together fragrance experts, educators, creators and community leaders with Coty's fragrance teams. Through discussions, workshops, immersive experiences and co-creation opportunities, members will...

Can Coty's New Product Launches Accelerate Its Growth Momentum?

Coty's innovation-led strategy, strong prestige fragrance and cosmetics sales, and upcoming launches across major brands could accelerate its growth momentum.

How Helen of Troy Is Building a More Consumer-Led Brand Strategy

HELE is sharpening its consumer-led strategy with faster decisions, focused innovation and closer alignment across brands, products and markets.

Coty Americas LFL Sales Rise 6%: What Is Driving Regional Strength?

COTY's Americas business gained momentum in fiscal Q4, driven by strength in the U.S., Brazil and Travel Retail as key beauty brands improved.

Coty Q4 2026 Earnings Call Transcript

Coty (NYSE:COTY) released fourth-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This transcript is brought to you by Benzinga APIs. For real-time access to ourread more...

Why Is Coty (COTY) Down 10.6% Since Last Earnings Report?

Coty (COTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Coty, Inc. engages in the manufacture, market, sale, and distribution of branded beauty products. It operates through the following segments: Prestige, Consumer Beauty, and Corporate. The company was founded by Francois Coty in 1904 and is headquartered in New York, NY.

Coty Inc - Ordinary Shares - Class A

COTY Stock Tumbles 6% Overnight: Beauty Giant Flags ‘Transition Year’ Ahead

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Coty’s Q4 adjusted operating income fell 42%, margins declined, and full-year revenue dropped 2% to $5.81 billion.&nbsp;&nbsp;</li><li>The company sees Q1 EPS below Wall Street’s Expectations.&nbsp;</li><li>Interim CEO Markus Strobel said fiscal 2027 will focus on strengthening core brands.</li></ul>Coty Inc. (COTY) stock reversed course and tumbled 6% overnight after the beauty company posted fourth-quarter (Q4) sales above expectations but reported a larger-than-anticipated loss and warned investors that next fiscal year will focus on restructuring rather than growth.<h2 class="st-heading-2">Coty’s Margins Come Under Pressure&nbsp;</h2>Coty’s mixed quarter and guarded outlook have renewed questions about the pace of its turnaround. Coty generated $1.27 billion in Q4 revenue, 1% higher than the same period last year, beating Wall Street’s $1.2 billion forecast, according to Fiscal Ai data. However, comparable sales slipped 1%, while adjusted earnings showed a loss of $0.02 per share, below analysts' estimate of a loss of $0.01.Profit suffered as Q2 adjusted operating income sank 42% to $39.5 million, while gross margin contracted 140 basis points to 60.9%. Higher tariffs, weaker manufacturing-cost absorption and additional charges tied to excess inventory weighed on results.For the full year, revenue declined 2% to $5.81 billion. Coty also moved from operating income of $241.1 million a year earlier to an $81.5 million loss, while its reported net loss expanded to $618 million.<a href="https://stocktwits.com/symbol/COTY"> Coty stock</a> traded 6.6% lower overnight, ahead of Thursday, after clocking its best day in a year in the regular session.&nbsp;<h2 class="st-heading-2">Fiscal 2027 Brings More Uncertainty For Coty&nbsp;</h2>The company expects comparable revenue to fall by a low-to-mid-single-digit percentage in the first quarter. Adjusted EBITDA is projected to decline by a low-teens percentage, while adjusted EPS is expected between $0.11 and $0.13, compared to Street estimates of $0.14."In sum, our Q4 results provide early signs of stabilization, although the recovery will not be linear. FY27 will be a transition year as we strengthen our core business and continue shaping a simpler, more focused Coty, factoring in both the Gucci exit by FY28 and final portfolio decisions related to our strategic review of Consumer Beauty by the end of CY26,” said Interim CEO Markus Strobel.&nbsp;Strobel added that beauty demand remains strong, especially for fragrances and cosmetics, but shoppers are becoming more careful about what they buy.“Consumers are increasingly selective in their purchase decisions, which is manifesting in several ways, in some cases benefiting more premium brands and products, and in other cases benefiting more accessible offerings.”&nbsp;<h2 class="st-heading-2">COTY Stock: Retail View&nbsp;</h2>However, on Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;A user&nbsp;<a href="https://stocktwits.com/blocktrade/message/662346838">said</a>, “if you ever hear “transition year” in a press release, just assume you will lose at a minimum 15%.”Another user&nbsp;<a href="https://stocktwits.com/DrMunch/message/662348228">said</a>, “Numbers gonna suffer a bit, partly or largly from getting out of Gucci deal. But they got $400 million out of that. Thats a big balance sheet plus.”COTY stock has dropped nearly 2% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nke-stock-in-focus-10-k-invested-in-nike-a-decade-ago-would-have-lost-money-despite-pandemic-era-surge/cZYdapURJkV">NKE Stock In Focus: $10K Invested In Nike A Decade Ago Would Have Lost Money Despite Pandemic-Era Surge</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Coty Inc company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Coty stock came under pressure after a wider loss and a cautious outlook.

Invesco S&P SmallCap 600 Pure Value ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.40
Prev Close	$3.35
Open	$3.39
Dividend Yield	0.00%
50-Day Moving Average	$2.84
Beta	0.97
Avg. Volume	5.18M
PE Ratio	-4.77

52-Week High	$4.16
52-Week Low	$1.82
Market Capitalization	$2.95B
EPS (Annual)	-$0.7044
Price to Book	0.99
Revenue Per Employee	$512,271.72

Feed

News

Sentiment

Earnings

Fundamentals

Info

COTY Fundamentals